Citation for published version (APA):
SleepSight: A wearables-based relapse prevention system for Schizophrenia

Maximilian Kerz  
King’s College London  
16 De Crespigney Park, SE5 8AF, United Kingdom  
maximilian.kerz@kcl.ac.uk

Amos Folarin  
King’s College London  
16 De Crespigney Park, SE5 8AF, United Kingdom  
amos.folarin@kcl.ac.uk

Nicholas Meyer  
King’s College London  
16 De Crespigney Park, SE5 8AF, United Kingdom  
nicholas.meyer@kcl.ac.uk

Mark Begale  
Northwestern University  
750 N Lake Shore Dr, 60611, United States  
m-begale@northwestern.edu

James MacCabe  
King’s College London  
16 De Crespigney Park, SE5 8AF, United Kingdom  
james.maccabe@kcl.ac.uk

Richard Dobson  
King’s College London  
16 De Crespigney Park, SE5 8AF, United Kingdom  
richard.j.dobson@kcl.ac.uk

Permission to make digital or hard copies of part or all of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for third-party components of this work must be honored. For all other uses, contact the Owner/Author. Copyright is held by the owner/author(s).

UbiComp/ISWC ’16 Adjunct, September 12-16, 2016, Heidelberg, Germany ACM 978-1-4503-4462-3/16/09.  
http://dx.doi.org/10.1145/2968219.2971419

Abstract

SleepSight is a novel approach to detecting early signs of relapse in psychosis, thereby allowing targeted intervention for relapse prevention. The system uses a wireless-enabled wearable device and smartphone to collect longitudinal accelerometry, heart-rate, ambient light and smartphone usage patterns from patients living in their homes. These data are encrypted and sent via the mobile data network to a secure server for real-time analysis, using the Purple Robot mobile application.

This study tested feasibility and acceptability of the SleepSight system in 15 participants with a diagnosis of schizophrenia. Patient recruitment and data collection was completed in January 2016, at the South London and Maudsley NHS Foundation Trust (SLaM), the largest mental health service provider in the EU. The project is a unique multidisciplinary collaboration between the NIHR Biomedical Research Centre for Mental Health, the Institute of Psychiatry, Psychology and Neuroscience, and the National Health Service.
Introduction

Schizophrenia manifests itself as positive symptoms, including delusions, hallucinations and thought disorder as well as negative symptoms, including abnormal social behaviour and withdrawal. Therapeutic treatments often require an initial phase of dose adjustment to take effect and may result in a loss of drug efficacy, requiring dose readjustment with disease progression (Eisner, 2013). Around 80% of those treated for a first episode of psychosis relapse within five years (Robinson et al., 1999). This is partly due to limitations with self-reports, questionnaires and fortnightly or monthly screening as intervention measures in community based patients.

Early signs of relapse in Schizophrenia

Most relapse prevention strategies rely on self or observer-rated early warning signs (EWS) such as anxiety, dysphoria, and poor concentration that manifest prior to relapse (Eisner et al 2013). However, sensitivity and specificity have been modest, and are limited by infrequent assessment and loss of insight. Objective, physiological markers which can be sampled continuously are likely to have greater precision, place less burden on the user and thereby improve adherence, and allow passive monitoring to continue even once insight has been lost (Figure 1).

In clinical practice, disturbance in normally rhythmically organised behaviours such as the sleep-wake cycle and activity and arousal levels are frequently observed in individuals presenting during relapse, and are cited in retrospect by patients and their carers as precursors to relapse (e.g. Herz et al 1980). Such disturbances are now readily measurable using accelerometers and optical heart-rate monitors embedded in wearable and mobile technologies, and may serve as clinically useful early indicators of relapse.
Methodology

Study design
The study involved the recruitment of 16 participants all of whom suffered from Schizophrenia. Each participant was given a smartphone (Nexus 5) as well as a wearable device (Fitbit Charge HR) and was monitored for a period of 8 weeks.

The PANSS
The positive and negative symptom scale (PANSS) is used to measure symptom severity in patients with Schizophrenia. The scale was introduced in 1987 and is now a widely used tool in the realm of antipsychotic therapy. 
Data acquisition

The Purple Robot framework, developed by the Centre for Behavioural Intervention Technology (CBITS) at Northwestern University, provides an interface to on-board mobile phone probes (e.g. GPS, light, temperature) and a framework for integrating other mobile-aware probes e.g. wearables featuring accelerometers, oxygen saturation, heart rate, blood pressure, blood glucose. Using this platform, we have built a framework to enable patient reported outcome (PROM) data from smartphone applications, smartphone sensors and other sensor devices to be collected and analysed.

The SleepSight platform

The SleepSight platform was developed with the design criteria of device-agnosticism, reliability and user-acceptance in mind (Figure 2). As result we decided to utilise the Fitbit Charge HR, featuring an optical heart rate sensor and accelerometer, as wearable. The Nexus 5 had the Purple Robot and Fitbit mobile app installed to upload their data to our secure King’s College London (KCL)- and Fitbit’s server, respectively. Additionally, the phone featured a proprietary SleepSight app which would ask the participant to submit a sleep diary and PANSS-like questionnaire on a daily basis. The questionnaire data was used to complement the passively collected data set as labels.

Finally, once the data arrived on our KCL server, we employed a probabilistic model to detect anomalies in each participant’s behavior, individually.

Data analysis

There are many ways to disseminate valuable information from a multivariate high resolution time series. In our case we wanted to prioritise quantification of our participant’s behavior and detect early signs of relapse.

In order to achieve the latter, we trained a generalising Gaussian Process (GP) with a periodic (sinusoid) kernel on days on which a participant scored particularly low
symptom scores. Deviations from this model could then be quantified and evaluated (Figure 3).

**Results**
The study included 16 participants of which 14 completed the study successfully based on our acceptability criteria of at least 70% wear-time and questionnaire submission over a period of 8 weeks (days n=56). Figure 4 shows user acceptance in more detail.

Our GP anomaly detection methodology is still a work in progress and hence we are unable to present valuable results regarding behavior quantification at this point.

**References**